Will Kaback
speaker
1,313 appearances
13 recordings
1 series
first heard Aug 2026
last heard 5d ago
Will Kaback’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 13 in all, peaking in Sep 2026 with 12.
Appearances
Not long ago, addressing America's obesity epidemic was seen as something only the government could solve by micromanaging consumers' eating habits.
As is often the case, however, science-based innovation has proven far more effective than any initiative from Washington.
In National Review, John R. Puri said, don't ruin GLP-1 prices by having the government cover them.
Over the past few years, the American healthcare sector has seen a real-time experiment in what happens when a revolutionary treatment runs outside traditional payment systems.
Usually, when the FDA approves a new drug, its cost is quickly covered by employer-run insurance plans and the government through Medicare and Medicaid.
Yet the makers of GLP-1 drugs approved for weight loss have had to compete for patients' dollars more directly.
Individual patients may be annoyed that insurance won't pick up the tab on a pricey brand-name drug, but the result of widespread self-payment has been vicious price competition to win market share.
The price of GLP-1 drugs will probably keep falling, but only if patients have to pay for the drugs themselves.
Governments should limit their appetite for providing short-term relief at long-term expense.
And in the Daily Wire, Benjamin Chacko asked, are we using medicinal drugs to support healthy living or as a substitute for it?
One extreme dismisses GLP-1s as another miracle cure sold by Big Pharma.
The other imagines that a weekly injection can replace the hard work of building health.
Both are false gods.
Disease begins with what we eat, how we sleep, how we move, and a food environment that has been for decades making processed calories cheaper, more addictive, and more accessible than real nutrition.
The Make America Healthy Again movement is rightly focused on those upstream causes.
GLP-1s should complement that mission, not compete with it.
Medicine is crossing an important threshold as we develop drugs that will influence motivation, reward, and desire themselves.
It's an extraordinary scientific achievement, but it also demands extraordinary wisdom.
We know GLP-1s work, but they cannot replace the habits, character, and choices that allow people to flourish.
The question at hand is whether we'll use them to support health or substitute for it.
Showing 41–60 of 1,313 · page 3 of 66
← Previous
Next →